SmallCapSociety

Society Pick of The Week

Predictive Oncology (NASDAQ: POAI)

Predictive Oncology (NASDAQ: POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Considerations:

  • Helomics is collaborating with the University of Pittsburgh School of Medicine to study the use of artificial intelligence to improve clinical decision making for ovarian cancer patients. More than 22,000 women are diagnosed with ovarian cancer in the U.S. each year.
  • Entered an agreement with Interpace Diagnostics Group Inc. (IDXG) and Helomics to develop products to diagnose and assess the risk for thyroid cancer as well as provide appropriate therapeutic recommendations. The treatment market for thyroid cancer is expected to reach $2.1 billion by 2025.
  • Skyline Medical has received its first order for four STREAMWAY machines to be sold to local hospitals in India. The Indian healthcare industry is estimated at more than $100 billion, with the nation’s medical device industry valued at more than $6 billion.
  • Helomics signed a collaborative research agreement with Pittsburgh-based molecular imaging company, ChemImage, to expand personalized medicine to prostate cancer diagnosis and treatment.
  • TumorGenesis and partner 48Hour Discovery received the Alberta Innovates grant for development of novel cancer treatments.
View Complete Profile

Interact with SmallCapSociety Members

follow us on twitter    like us on facebook

Network Partner Spotlight
SmallCapRelations

About SmallCapSociety

Our focus is on micro- and small-cap companies spanning a range of industries and stages of development. The stocks that catch our attention feature the products, services, management teams and business plans required to thrive in today's markets. For the knowledgeable investor, the small-cap space represents huge potential, but keeping abreast of the latest happenings in specific industry sectors and niches is essential to optimizing long-term returns. We're not interested in selling snake oil or touting the so-called "hottest" stocks. We're all about giving you the tools and information needed to uncover ground-floor plays that are ripe for big-time moves.

Newsletter archives and disclaimers available at: www.smallcapsociety.com

SmallCapSociety is part of the InvestorBrandNetwork.

SmallCapSociety (SCS) | Los Angeles, CA
Contact The Editor | Unsubscribe me from this mailing list